Charles River Laboratories International, Inc. (NYSE: CRL) has announced that its neuroscience drug discovery team will present 18 scientific posters at Neuroscience 2024, the annual meeting of the Society for Neuroscience (SfN). These presentations will include both independent research and collaborative work with clients. The event, which gathers leading researchers worldwide, will be held from October 5-9 in Chicago, IL.
“Charles River is dedicated to transforming neuroscience research,” said Antti Nurmi, Ph.D., MSc, General Manager of CNS Pharmacology at Charles River. “We aim to provide deep translational expertise as a trusted partner in preclinical models, innovative drug discovery, manufacturing, and commercialization, ultimately leading to better outcomes for our clients and patients.”
Partnering with World-Class Scientists
Recent advances in genetics, pathology, biomarkers, and endpoints are propelling momentum in neuroscience drug discovery, from small molecules to advanced therapies. During the conference, Charles River experts will present posters and facilitate discussions on the latest developments in neuroscience research and innovative approaches to neurodegenerative disorders. Highlights include:
- In Vitro Co-Culture Model for Myelination: Presented by Malika Bsibsi on Sunday, October 6, 2024, from 4:00-5:00 p.m. CDT.
- iPSC-Derived Neuroinflammation Model: Presented by Malika Bsibsi on Monday, October 7, 2024, from 2:00-3:00 p.m. CDT.
Building Collective Momentum
On Monday, October 7, at 10:00 a.m. CDT in Product Theater 2, Charles River’s scientific experts will discuss how recent advances in genetics, pathology, biomarkers, and endpoints in ALS research are impacting drug discovery for this progressive neurodegenerative disease. Susanne Back, Ph.D., Senior Manager of CNS Pharmacology, and Philip Mitchell, Ph.D., Director of Integrated Biology, will explain how cellular and animal models can replicate disease pathology and support clinical success for small molecules, ASOs, and gene therapies.
Charles River’s global team of nearly 200 neuroscientists spans drug discovery and development, from basic research to regulatory approval, providing the translational science and collaborative approach essential for discovering novel therapies. Since 2018, the company has supported 80% of new neuroscience drugs approved by the U.S. Food and Drug Administration (FDA).
Recent initiatives highlight Charles River’s comprehensive approach to neurodegenerative diseases, including a strategic collaboration with CEBINA to advance cutting-edge neuroscience research and the integration of Insightec’s low-frequency ultrasound platform for precise therapeutic delivery to deep brain structures. Additionally, the AI-powered Logica® drug discovery solution, developed in partnership with H. Lundbeck A/S, utilizes Valo Health’s Opal Computational Platform™ to optimize preclinical candidates for brain disease research.
A full schedule of Charles River’s activities at Neuroscience 2024 is available online. Experts will also be present at Booth #417 for discussions on neuroscience research and drug discovery.
About Charles River
Charles River provides essential products and services to pharmaceutical and biotechnology companies, government agencies, and leading academic institutions worldwide, helping to accelerate research and drug development. Our dedicated team focuses on delivering exactly what clients need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for patients in need.
